News >

Metastatic TNBC Paradigm Continues to Evolve With Novel Treatments

Caroline Seymour
Published: Thursday, Jan 16, 2020

Howard A. Burris, III, MD, FACP, FASCO, chief medical officer and president of Clinical Operations at Sarah Cannon Research Institute

Howard A. "Skip" Burris, III, MD, FACP, FASCO

Immunotherapy, PARP inhibitors, and antibody-drug conjugates (ADCs) have shown clinical benefit in patients with metastatic triple-negative breast cancer (TNBC). The use of these treatments is guided in part by the predictive value of PD-L1 expression and BRCA mutations, explained Howard A. "Skip" Burris, III, MD, FACP, FASCO.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication